Trials / Completed
CompletedNCT00591994
Tinnitus Treatment With Piribedil Guided by Acoustic Otoemissions and Electrocochleography
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 100 (actual)
- Sponsor
- Faculdade de Medicina de Valenca · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Tinnitus is defined as the perception of sound in the absence of a external source. About 15 % of the population is believed to experience tinnitus and for about 20 % of them it may become a very serious problem. Total comprehension of tinnitus pathophysiology has not yet been achieved, but modern theories focus in brain hyperactivity following inner ear damage, with involvement of various neurotransmitters. Piribedil,a dopamin agonist, has been used to treat tinnitus, focusing in dopamine release, which is inhibitory. Electrophysiological methods,like acoustic otoemissions and electrocochleography may reveal the changes in peripherical and central auditory pathways and help to choose the specific patients who could benefit from piribedil treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | piribedil | 50 mg once a day, after lunch 3 month therapy |
Timeline
- Start date
- 2006-11-01
- Primary completion
- 2007-12-01
- First posted
- 2008-01-11
- Last updated
- 2008-03-07
Locations
1 site across 1 country: Brazil
Source: ClinicalTrials.gov record NCT00591994. Inclusion in this directory is not an endorsement.